Part three of a peptide series says semaglutide targets one receptor, tirzepatide two and the still-experimental retatrutide three. Two more parts are planned.
Recap by typeshit. Post by Facebook on Facebook.
The review looks at concerns about misuse as demand for GLP-1 drugs grows, and points to how little evidence guides their use beyond approved conditions.
Researchers found self-reported GLP-1 use climbed from March 2024 to October 2025, mostly for weight loss, through channels insurance data may not capture.
The study is looking for women with hot flashes and night sweats and a BMI above 30. Mayo Clinic has the full eligibility rules and how to sign up.
A matched cohort study in Inflammatory Bowel Diseases found remission odds nearly six times higher on GLP-1 drugs, and weight loss alone didn't explain it.
The same variant also raised odds of nausea and vomiting, and tirzepatide users carrying two variants had 14.8 times the odds of vomiting, researchers report.
The series sorts the three drugs by how many receptors each one targets, from one to three, and notes retatrutide is still under investigation. Two more peptides are promised.
Loading…